Korro Bio, Inc.

Equities

KRRO

US5009461089

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
54.66 ^USD	+6.63%		-0.40%	+14.04%

05-15	HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating	MT
05-14	Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	MT

Frequency Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 10, 2023 at 12:41 pm

Frequency Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 81.58 million compared to USD 84.69 million a year ago. Basic loss per share from continuing operations was USD 116.5 compared to USD 123.5 a year ago.

Latest news about Korro Bio, Inc.

HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating	05-15	MT
Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	05-14	MT
Korro Bio, Inc. Announces the Appointment of Kemi Olugemo, M.D. as Chief Medical Officer	05-14	CI
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	04-24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	04-24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	04-24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	04-24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	04-24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	04-24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	04-24	MT
Korro Bio, Inc. announced that it has received $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc.	04-21	CI
Korro Bio, Inc. announced that it expects to receive $69.959848 million in funding from Atlas Venture L.P.	04-16	CI
HC Wainwright Adjusts Korro Bio's Price Target to $115 From $100, Buy Rating Kept	03-28	MT
RBC Boosts Price Target on Korro Bio to $90 From $70 on 'Increased Conviction for A1AT,' Keeps Outperform, Speculative Risk	03-27	MT
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
North American Morning Briefing : Stocks Struggle After New Records	03-22	DJ
North American Morning Briefing : Inflation -2-	03-15	DJ
BMO Capital Initiates Korro Bio With Outperform Rating, Price Target is $120	02-27	MT
Korro Announces Selection of Its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency	12-07	CI
HC Wainwright Starts Korro Bio With Buy Rating, $100 Price Target	12-04	MT
RBC Initiates Korro Bio at Outperform, Speculative Risk With $70 Price Target, Says Lead Program 'May Be Best-in-Class' for A1AT Protein	11-29	MT
Korro Bio, Inc. Appoints Rachel Meyers as Board of Directors, Member of Nominating and Corporate Governance Committee	11-28	CI
Piper Sandler Starts Coverage on Korro Bio with Overweight Rating, $180 Price Target	11-10	MT
Frequency Therapeutics, Inc.(NasdaqCM:FREQ) dropped from NASDAQ Composite Index	11-03	CI
Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. from a group of shareholders.	11-02	CI

Chart Korro Bio, Inc.

Duration

Period

More charts

Company Profile

Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the bodyâs natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Companyâs first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

51.26 USD

Average target price

126.2 USD

Spread / Average Target

+146.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KORRO BIO, INC.	+14.04%	475M
MODERNA, INC.	+33.63%	50.85B
IQVIA HOLDINGS INC.	-0.09%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	19.13B
BIO-TECHNE CORPORATION	+8.61%	13.05B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.08B

Other Biotechnology & Medical Research